Search research articles
Contact Us
Filters
Showing results (11-20 of 128) with videos related to
Page
of 13
Sort By:
BMC Medical Research Methodology
|
November 26, 2020
Correction to: Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint
Xieran Li, Carolin Herrmann, Geraldine Rauch
Journal of Biopharmaceutical Statistics
|
May 25, 2022
Two-stage designs with small sample sizes
Meinhard Kieser, Geraldine Rauch, Maximilian Pilz
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
May 31, 2019
[Research involving human subjects-principles and challenges for the work of ethics committees]
Iris Pigeot, Ulrich Mansmann, Geraldine Rauch
Journal of Biopharmaceutical Statistics
|
December 31, 2010
A new outlier identification test for method comparison studies based on robust regression
Geraldine Rauch, Andrea Geistanger, Jürgen Timm
BMC Medical Research Methodology
|
February 7, 2020
Why do you need a biostatistician?
Antonia Zapf, Geraldine Rauch, Meinhard Kieser
Statistical Methods in Medical Research
|
July 25, 2023
Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
Dario Zocholl, Cornelia U Kunz, Geraldine Rauch
BMC Medical Research Methodology
|
January 6, 2018
A systematic comparison of recurrent event models for application to composite endpoints
Ann-Kathrin Ozga, Meinhard Kieser, Geraldine Rauch
BMC Medical Research Methodology
|
March 28, 2024
Optimal futility stopping boundaries for binary endpoints
Michaela Maria Freitag, Xieran Li, Geraldine Rauch
Methods of Information in Medicine
|
May 3, 2018
The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
Geraldine Rauch, Werner Brannath, Matthias Brückner, et al.
Statistics in Medicine
|
October 9, 2018
What makes a biostatistician?
Antonia Zapf, Marianne Huebner, Geraldine Rauch, et al.
Page
of 13
Search research articles
Search
Showing results (11-20 of 128) with videos related to
Sort By:
Page
of 13
BMC Medical Research Methodology
|
November 26, 2020
Correction to: Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint
Xieran Li, Carolin Herrmann, Geraldine Rauch
Journal of Biopharmaceutical Statistics
|
May 25, 2022
Two-stage designs with small sample sizes
Meinhard Kieser, Geraldine Rauch, Maximilian Pilz
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
May 31, 2019
[Research involving human subjects-principles and challenges for the work of ethics committees]
Iris Pigeot, Ulrich Mansmann, Geraldine Rauch
Journal of Biopharmaceutical Statistics
|
December 31, 2010
A new outlier identification test for method comparison studies based on robust regression
Geraldine Rauch, Andrea Geistanger, Jürgen Timm
BMC Medical Research Methodology
|
February 7, 2020
Why do you need a biostatistician?
Antonia Zapf, Geraldine Rauch, Meinhard Kieser
Statistical Methods in Medical Research
|
July 25, 2023
Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
Dario Zocholl, Cornelia U Kunz, Geraldine Rauch
BMC Medical Research Methodology
|
January 6, 2018
A systematic comparison of recurrent event models for application to composite endpoints
Ann-Kathrin Ozga, Meinhard Kieser, Geraldine Rauch
BMC Medical Research Methodology
|
March 28, 2024
Optimal futility stopping boundaries for binary endpoints
Michaela Maria Freitag, Xieran Li, Geraldine Rauch
Methods of Information in Medicine
|
May 3, 2018
The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
Geraldine Rauch, Werner Brannath, Matthias Brückner, et al.
Statistics in Medicine
|
October 9, 2018
What makes a biostatistician?
Antonia Zapf, Marianne Huebner, Geraldine Rauch, et al.
Page
of 13